Abstract:Therapeutic Advances in Chronic Disease, Volume 15, Issue , January-December 2024. Background:Currently, there are no biomarkers for migraine.Objectives:We aimed to identify proteomic biomarker signatures for diagnosing, subclassifying, and predicting treatment response in migraine.Design:This is a cross-sectional and longitudinal study of untargeted serum and cerebrospinal fluid (CSF) proteomics in episodic migraine (EM; n = 26), chronic migraine (CM; n = 26), and healthy controls (HC; n = 26).Methods:We developed classification models for biomarker identification and natural clusters through unsupervised classification using agglomerative hierarchical clustering (AHC). Pathway analysis of differentially expressed proteins was performed.Results:Of 405 CSF proteins, the top five proteins that discriminated between migraine patients and HC were angiotensinogen, cell adhesion molecule 3, immunoglobulin heavy variable (IGHV) V-III region JON, insulin-like growth factor binding protein 6 (IGFBP-6), and IGFBP-7. The top-performing classifier demonstrated 100% sensitivity and 75% specificity in differentiating the two groups. Of 229 serum proteins, the top five proteins in classifying patients with migraine were immunoglobulin heavy variable 3-74 (IGHV 3-74), proteoglycan 4, immunoglobulin kappa variable 3D-15, zinc finger protein (ZFP)-814, and mediator of RNA polymerase II transcription subunit 12. The best-performing classifier exhibited 94% sensitivity and 92% specificity. AHC separated EM, CM, and HC into distinct clusters with 90% success. Migraine patients exhibited increased ZFP-814 and calcium voltage-gated channel subunit alpha 1F (CACNA1F) levels, while IGHV 3-74 levels decreased in both cross-sectional and longitudinal serum analyses. ZFP-814 remained upregulated during the CM-to-EM reversion but was suppressed when CM persisted. CACNA1F was pronounced in CM persistence. Pathway analysis revealed immune, coagulation, glucose metabolism, erythrocyte oxygen and carbon dioxide exchange, and insulin-like growth factor regulation pathways.Conclusion:Our data-driven study provides evidence for identifying novel proteomic biomarker signatures to diagnose, subclassify, and predict treatment responses for migraine. The dysregulated biomolecules affect multiple pathways, leading to cortical spreading depression, trigeminal nociceptor sensitization, oxidative stress, blood–brain barrier disruption, immune response, and coagulation cascades.Trial registration:NCT03231241, ClincialTrials.gov.Plain language summaryIdentification of biological markers for migraine using proteins found in the cerebrospinal fluid and bloodThe diagnosis of migraine currently relies on self-reported symptoms. Inaccurate reporting by patients and inadequate interviewing by diagnosticians can result in misdiagnosis and subsequent mistreatment. Our study investigated the disparity in protein levels in the cerebrospinal fluid (CSF) and serum between individuals with migraine and healthy individuals. Our study provides evidence for identifying novel protein biomarkers and biological pathways that can assist in diagnosing, subclassifying, and predicting treatment responses for migraine.

Lipidomic Analysis of Serum Samples from Migraine Patients

Serum Metabolites Differentiate Amnestic Mild Cognitive Impairment From Healthy Controls And Predict Early Alzheimer'S Disease Via Untargeted Lipidomics Analysis

Low Levels of Serum Serotonin and Amino Acids Identified in Migraine Patients.

Targeted Metabolomics Based on LC-MS/MS Revealing Alteration of Bile Acids in Male Migraine Patients

Deep and unbiased proteomics, pathway enrichment analysis, and protein–protein interaction of biomarker signatures in migraine

Identification of Serum Biomarkers of Ischemic Stroke in a Hypertensive Population Based on Metabolomics and Lipidomics

A Preliminary Study on Change of Serum Immunoglobulin G Glycosylation in Patients With Migraine

Metabolic profile changes in serum of migraine patients detected using 1H-NMR spectroscopy

Lipidomic Profiling of Plasma Samples from Patients with Mitochondrial Disease.

Mendelian randomization study of lipid metabolism characteristics and migraine risk

Exploring PGE2 and LXA4 Levels in Migraine Patients: The Potential of LXA4-Based Therapies

In-depth cerebrovascular lipidomics profiling for discovering novel biomarkers and mechanisms in moyamoya and intracranial atherosclerotic disease

Serum Lipids Profiling Perturbances in Patients with Ischemic Heart Disease and Ischemic Cardiomyopathy

Lipid profile of cerebrospinal fluid in multiple sclerosis patients: a potential tool for diagnosis

Pharmacokinetic and Lipidomic Assessment of the In Vivo Effects of Parishin A-Isorhynchophylline in Rat Migraine Models

Metabolomic profiling integrated with molecular exploring delineates the action of Ligusticum chuanxiong hort. on migraine

Identification and quantification of the quality markers and anti-migraine active components in Chuanxiong Rhizoma and Cyperi Rhizoma herbal pair based on chemometric analysis between chemical constituents and pharmacological effects

Bioinformatic Analysis from a Descriptive Profile of miRNAs in Chronic Migraine

Search for serum biomarkers in patients with bipolar disorder and major depressive disorder using metabolome analysis

Metabolomic Profiling of Fatty Acid Biomarkers for Intracerebral Hemorrhage Stroke.

Identification of disease- and headache-specific mediators and pathways in migraine using blood transcriptomic and metabolomic analysis